Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trials

6 recruiting trials for Attention Deficit Hyperactivity Disorder (ADHD). Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
6
Total Trials
6
Recruiting Now
0
Phase 3 Trials
5
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 2NCT06967857

Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and...

The indication of attention-deficit/hyperactivity disorder (ADHD) to be examined often occurs with other psychiatric disorders, and the majority of adults with ADHD have at least...

Sponsor: Prof. Dr. Frank BehrensEnrolling: 1052 locations
RECRUITINGPhase 2 / Phase 3NCT07086313

A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD

The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in pediatric ADHD patients.

Sponsor: Otsuka Pharmaceutical Co., Ltd.Enrolling: 3151 location
RECRUITINGNCT06858527

Deficit Hyperactivity Disorder / Substance Use Disorder Comorbidity in Integrated Treatment

Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUDs) is a highly common comorbid condition associated with serious medical and psychosocial...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 1321 location
RECRUITINGPhase 2 / Phase 3NCT06931080

Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients

The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.

Sponsor: Otsuka Pharmaceutical Co., Ltd.Enrolling: 6301 location
RECRUITINGNCT06221358

Pharmacogenomics of Stimulant Treatment Response

The "Pharmacogenomics of Stimulant Treatment Response" (PGx-STaR) study aims to identify genetic profiles related to methylphenidate treatment outcomes in children and adolescents...

Sponsor: University of CalgaryEnrolling: 4001 location
RECRUITINGPhase 2NCT06542445

The Safety and Efficacy of Terpene-enriched Cannabidiol (CBD) Oil in ADHD

ADHD is the most frequent neurodevelopmental disorder in childhood. Symptoms often appear in preschool years, and most children (65-80%) continue to experience some...

Sponsor: Bazelet Nehushtan LtD.Enrolling: 1201 location

Frequently Asked Questions

There are currently 6 clinical trials for Attention Deficit Hyperactivity Disorder (ADHD), with 6 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Attention Deficit Hyperactivity Disorder (ADHD), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Attention Deficit Hyperactivity Disorder (ADHD), representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.

For this entity, the underlying data on this page comes from the NIH ClinicalTrials.gov registry. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.

Every number on this page links back to the NIH ClinicalTrials.gov registry; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within active and historical clinical trials with similar size, similar exposure, or similar geography — not the national-level summary alone.